Scholarlink

<p>Breast cancer remains one of the most lethal diseases for women worldwide. Marine populations are considered a vast reservoir for novel bioactive metabolites, particularly marine Actinomycetes, which are known to produce various bioactive compounds with antitumour, antibacterial, and antifungal properties. A promising new marine strain was isolated and identified as <i>Streptomyces albidoflavus</i> strain EgyAB2 (16&#xa0;S rRNA gene sequence accession number ON680945.1). The anticancer activity of the extracted compounds was tested in the MCF7 cell line using a sulforhodamine B (SRB) bioassay, which revealed an IC<sub>50</sub> of 0.36&#xa0;µg/ml compared to the chemotherapeutic drug 5-fluorouracil (0.35&#xa0;µg/ml). Additionally, the anticancer activity was confirmed by a dimethyl-thiazol-diphenyl-tetrazolium bromide (MTT) bioassay, which showed an IC<sub>50</sub> of 17.46&#xa0;µg/ml. The mode of action of the treated breast carcinoma (apoptotic effect) was studied via qRT-PCR, revealing a significant role in anticancer treatment. Although the extracted compounds exhibited high antioxidant activity in the diphenyl-2-picrylhydrazyl (DPPH) radical-scavenging assay, they presented an IC<sub>50</sub> of 8.92&#xa0;µg/ml and an inhibition percentage of 56.08%. Chemical characterisation was performed via GC‒MS, 1&#xa0;H-NMR, and FTIR spectroscopy analyses, revealing the presence of 2-D N-methyl imidazole, 2-nonadecene, 1-D-2-methyl imidazole, and propane dinitrile, all of which exhibit antitumour activity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the mechanisms and mode of action of bioactive compounds from marine Streptomyces albidoflavus against breast carcinoma cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月19日

查看全文
  • Abir M. Shata,
  • Mokhtar Saeed Rejili,
  • Manal M. El-Naggar,
  • Samy A. El-Asser,
  • Ahmed A. Saleh,
  • Elsayed E. Hafez,
  • Faouzi Haouala,
  • Amany S. Youssef

摘要

Breast cancer remains one of the most lethal diseases for women worldwide. Marine populations are considered a vast reservoir for novel bioactive metabolites, particularly marine Actinomycetes, which are known to produce various bioactive compounds with antitumour, antibacterial, and antifungal properties. A promising new marine strain was isolated and identified as Streptomyces albidoflavus strain EgyAB2 (16 S rRNA gene sequence accession number ON680945.1). The anticancer activity of the extracted compounds was tested in the MCF7 cell line using a sulforhodamine B (SRB) bioassay, which revealed an IC50 of 0.36 µg/ml compared to the chemotherapeutic drug 5-fluorouracil (0.35 µg/ml). Additionally, the anticancer activity was confirmed by a dimethyl-thiazol-diphenyl-tetrazolium bromide (MTT) bioassay, which showed an IC50 of 17.46 µg/ml. The mode of action of the treated breast carcinoma (apoptotic effect) was studied via qRT-PCR, revealing a significant role in anticancer treatment. Although the extracted compounds exhibited high antioxidant activity in the diphenyl-2-picrylhydrazyl (DPPH) radical-scavenging assay, they presented an IC50 of 8.92 µg/ml and an inhibition percentage of 56.08%. Chemical characterisation was performed via GC‒MS, 1 H-NMR, and FTIR spectroscopy analyses, revealing the presence of 2-D N-methyl imidazole, 2-nonadecene, 1-D-2-methyl imidazole, and propane dinitrile, all of which exhibit antitumour activity.